AIM ImmunoTech Inc. (AIM) stock

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$0.15+0.00 (+0.13%)

Close on Nov 12, 2026Market cap $4.52MP/E –Yield –

AIM ImmunoTech gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2014 it was -535.0%, against -722.7% the year before. The highest annual figure on record is -426.1% in fiscal 2009.

Period	Period end	Value	Change (pts)
FY2014	Dec 31, 2014	-535.0%	+187.6
FY2013	Dec 31, 2013	-722.7%	+111.1
FY2012	Dec 31, 2012	-833.8%	−286.0
FY2011	Dec 31, 2011	-547.8%	+345.5
FY2010	Dec 31, 2010	-893.3%	−467.2
FY2009	Dec 31, 2009	-426.1%	–

Parsed from the XBRL in AIM ImmunoTech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 12, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIM.

Advertisement
300 × 250

See a number that looks wrong?